Sygnis Pharma diagnostic news
Sygnis said it will reduce headcount by 10 (30%) to 23 and discontinue its KIBRA R&D project. The company said it was not possible to out-license the project within the available timeline and the project could not be continued with internal resources. As part of the project, Sygnis partnered with Cenix BioScience GmbH (Dresden, Germany) last year to use Cenix's Definiens XD image analysis system to develop and optimize RNAi-based high-content screening assays to validate targets for Sygnis. According to Sygnis, the KIBRA gene has been implicated in episodic human memory and the risk of developing Alzheimer's disease (AD). Earlier this month, Sygnis completed its acquisition of the X-Pol Biotech S.L. subsidiary of Genetrix S.L. (Madrid, Spain). X-Pol became a wholly owned subsidiary of Sygnis and will develop and market X-Pol's DNA sequencing technologies and products (see BioCentury, Nov. 21, 2011 & Dec. 10, 2012). ...